ClinicalTrials.gg
CompletedNCT04896008ZENITHUpdated May 29, 2026Results posted

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

A Phase 3 interventional study of Sotatercept and Placebo in Pulmonary Arterial Hypertension, sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA. Completed at 57 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
173
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing sotatercept in Pulmonary Arterial Hypertension — 7 open to participants now, 10 under way, 1 of them phase 3. sotatercept · Pulmonary Arterial Hypertension.

Enrollment
4th of 18
173 · median 44
Started
2021
with 2 others
Phase 3
5 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
5 of 18
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA

Among the 18 studies testing sotatercept in Pulmonary Arterial Hypertension, this one is the 4th largest by enrollment, is one of 3 that started in 2021, is one of 5 in phase 3, and was the 5th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

7 of the 18 studies testing sotatercept in Pulmonary Arterial Hypertension are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About sotatercept

sotatercept: first FDA approval 2024 (WINREVAIR), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing sotatercept in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to first event of all cause death, lung transplantation, or PAH worsening-related hospitalization of ≥24 hours, in participants with World Health Organization (WHO) functional class (FC) III or FC IV PAH at high risk of mortality.

Read the detailed description

This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate sotatercept when added to maximum tolerated background PAH therapy on time to first event of all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥24 hours, in participants with WHO FC III PAH or WHO FC IV PAH at high risk of mortality.

Participants who were eligible for this study presented with symptomatic PAH that was classified as idiopathic, heritable, drug- or toxin-induced, associated with connective tissue disease, or post-shunt correction.

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary, hypertension, sotatercept
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnostic right heart catheterization prior to screening confirming the diagnosis of WHO PAH Group 1 in any of the following subtypes:

    • Idiopathic PAH
    • Heritable PAH
    • Drug/toxin-induced PAH
    • PAH associated with CTD
    • PAH associated with simple, congenital systemic to pulmonary shunts at least 1 year following repair
  • Symptomatic PAH classified as WHO FC III or IV
  • REVEAL Lite 2.0 risk score of ≥9
  • Right heart catheterization performed during screening (or within 2 weeks prior to screening, if done at the clinical study site) documenting a minimum PVR of ≥5 Wood units and a pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) of ≤15 mmHg
  • Clinically stable and on stable doses of maximum tolerated (per investigator's judgment) double or triple background PAH therapies for at least 30 days prior to screening
  • Females of must:

    • Have 2 negative urine or serum pregnancy tests as verified by the investigator prior to starting study therapy; must agree to ongoing urine or serum pregnancy testing during the course of the study and until 8 weeks after the last dose of the study drug
    • If sexually active with a male partner, have used, and agree to use highly effective without interruption per protocol; for at least 28 days prior to starting the product, during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment
    • Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment
  • Male participants must:

    • Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions, and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy
    • Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment
  • Ability to adhere to study visit schedule and understand and comply with all protocol requirements
  • Ability to understand and provide written

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of pulmonary hypertension (PH) WHO Groups 2, 3, 4, or 5
  • Diagnosis of the following PAH Group 1 subtypes: -associated PAH and PAH associated with portal hypertension
  • Diagnosis of pulmonary veno-occlusive diseases or pulmonary capillary hemangiomatosis or overt signs of capillary and/or venous involvement
  • at screening above gender-specific (ULN), per local laboratory test
  • Baseline count \<50,000/mm3 (\<50.0 x 109/L) at screening
  • Baseline systolic blood pressure \<85 mmHg at screening
  • Pregnant or breastfeeding women
  • Serum or aspartate aminotransferase levels or total >3.0×ULN
  • Currently enrolled in or have completed any other product study within 30 days for small molecule drugs or within 5 half-lives for biologics prior to the date of signed
  • Prior exposure to sotatercept or known allergic reaction to sotatercept, its or luspatercept
  • History of pneumonectomy
  • Untreated more than mild obstructive sleep apnea
  • History of known pericardial constriction
  • History of restrictive or congestive cardiomyopathy
  • (ECG) with Fridericia's interval (QTcF) >500 ms during the screening period
  • Personal or family history of long QT syndrome or sudden cardiac death
  • \<45% on historical echocardiogram within 1 year prior to the screening visit
  • Any current or prior history of symptomatic coronary disease (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) in the past 6 months prior to the screening visit
  • Cerebrovascular accident within 3 months prior to the screening visit
  • Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease
  • Currently on dialysis or anticipated need for dialysis within the next 12 months
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
173 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants on background PAH therapy will be administered placebo by SC injection every 21 days

    Other: Placebo

  • Experimental
    Sotatercept

    Participants on background PAH therapy will be administered sotatercept by SC injection at a starting dose of 0.3 mg/kg, with a target dose of 0.7 mg/kg, every 21 days

    Drug: Sotatercept

Interventions

  • SC injection

    Also known as: MK-7962, ACE-011

  • OtherPlacebo

    Placebo-matched SC injection

06

What researchers measure

Primary outcomes

  1. Time to First Confirmed Morbidity or Mortality Event

    Morbidity or mortality events were defined as all-cause death, lung transplantation, or PAH worsening-related hospitalization of ≥24 hours. All events were adjudicated by a blinded, independent committee of clinical experts. Only adjudication-confirmed lung transplantation and PAH worsening-related hospitalization of ≥24 hours were included in the primary analysis. All deaths that are a first event for a participant were included regardless of adjudication. The time from randomization to the first confirmed morbidity or mortality event, calculated using the non-parametric Kaplan-Meier method, is presented.

    Time frame: Up to approximately 31 months

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. As pre-specified in the SAP, all deaths up to data cutoff, including among participants who completed or discontinued the study, were included except for those that occurred after enrollment in the long-term follow-up study (MK-7962-004) or after lung transplantation. The OS for participants, calculated using the non-parametric Kaplan-Meier method, is reported.

    Time frame: Up to approximately 31 months

  2. Transplant-free Survival

    Transplant-free survival was defined as the time from randomization to the first lung transplantation or death due to any cause. As pre-specified in the SAP, all deaths up to data cutoff, including among participants who completed or discontinued the study, were included except for those that occurred after enrollment in the long-term follow-up study (MK-7962-004) or after lung transplantation. Transplant-free survival for participants, calculated using the non-parametric Kaplan-Meier method, is reported.

    Time frame: Up to approximately 31 months

  3. Percentage of Participants Who Experienced a Mortality Event

    Mortality events were defined as death due to any cause throughout the study. As pre-specified in the SAP, all deaths up to data cutoff, including among participants who completed or discontinued the study, were included except for those that occurred after enrollment in the long-term follow-up study (MK-7962-004) or after lung transplantation. The percent of participants who experienced a mortality event is reported.

    Time frame: Up to approximately 31 months

  4. Change From Baseline in REVEAL Lite 2.0 Risk Score at Week 24

    REVEAL Lite 2.0 risk scoring is used to guide PAH treatment decisions. Total score uses 6 variables with each assessed based on contribution to mortality risk. Variables and sub-score ranges: eGFR (0, +1), WHO FC (-1, 0, +1, +2), SBP (0, +1), heart rate (0, +1), 6MWD (-2, -1, 0, +1), and NT-proBNP (-2, 0, +2). Sub-scores are added to a base score of +6 and a total score of 1 to 14 is obtained (≤5=low risk; 6,7=intermediate risk; ≥8=high risk). A higher score = higher risk. Median change and full ranges are reported based on observed data.

    Time frame: Baseline and Week 24

  5. Percentage of Participants Achieving a Low or Intermediate (≤7) REVEAL Lite 2 Risk Score at Week 24

    REVEAL Lite 2.0 risk scoring is used to guide PAH treatment decisions. Total score uses 6 variables with each assessed based on contribution to mortality risk. Variables and sub-score ranges: eGFR (0, +1), WHO FC (-1, 0, +1, +2), SBP (0, +1), heart rate (0, +1), 6MWD (-2, -1, 0, +1), and NT-proBNP (-2, 0, +2). Sub-scores are added to a base score of +6 and a total score of 1 to 14 is obtained (≤5=low risk; 6,7=intermediate risk; ≥8=high risk). A higher score = higher risk. Per SAP, participants who did not have a REVEAL risk score at Week 24 were considered as non-responders and multiple imputation was not conducted for this endpoint. Comparisons between this analysis reporting non-imputed data should not be made to other REVEAL analyses which included imputation of missing Week 24 data. The percentage of participants who achieved a low or intermediate REVEAL Lite 2.0 score at Week 24 is reported.

    Time frame: Week 24

  6. Change From Baseline in NT-proBNP Levels at Week 24

    NT-proBNP is secreted by cardiomyocytes in response to ventricular stretch and is an established noninvasive marker of ventricular dysfunction in patients with PAH. Blood samples were collected at baseline and at Week 24 to measure NT-proBNP levels. Median change and full ranges are reported based on observed data.

    Time frame: Baseline and Week 24

  7. Change From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 24

    mPAP is a hemodynamic variable associated with PAH severity and was measured measured at baseline and at Week 24 by right heart catheterization (RHC). Median change and full ranges are reported based on observed data.

    Time frame: Baseline and Week 24

  8. Change From Baseline in Pulmonary Vascular Resistance (PVR)

    PVR is a hemodynamic variable associated with PAH severity and was measured at baseline and at Week 24 by right heart catheterization (RHC). Median change and full ranges are reported based on observed data.

    Time frame: Baseline and Week 24

  9. Percentage of Participants Who Improve in WHO FC

    The severity of a participant's PAH symptoms was graded using the WHO FC system. WHO functional classification for PAH ranges from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). Participants who improve in WHO FC were classified into "Improved", "No change", or "Worsened" (Improved = reduction in FC; Worsened = increase in FC; No change = no change in FC). The percentage of participants who had improvement from baseline in WHO FC at the end of the treatment period is reported.

    Time frame: Baseline and up to approximately 31 months

  10. Change From Baseline in 6MWD at Week 24

    6MWD was measured using the 6-Minute Walk Test (6MWT). The 6MWT measures the distance covered in 6 minutes and is intended to measure changes in functional exercise capacity. Each participant's 6MWD was measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicated improvement in functional exercise capacity. Median change and full ranges are reported based on observed data.

    Time frame: Baseline and Week 24

  11. Change From Baseline in Cardiac Output (CO) at Week 24

    CO is a prognostic hemodynamic parameter measured at baseline and at Week 24 by RHC. Median change and full ranges are reported based on observed data.

    Time frame: Baseline and Week 24

  12. Change From Baseline in European Quality of Life (EuroQoL)-5 Dimensions-5 Levels (EQ-5D-5L) Index Score at Week 24

    EQ-5D-5L is a standardized measure of health status, consisting of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each assessed on a 5-point scale (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems). Participants score each dimension based on their health that day and their responses are used to generate a health index score. Index scores could range from \<0 (a health state equivalent to dead with negative values representing a state worse than dead) to 1 (full health). Higher scores indicated better health and a positive change in score indicated improved overall health. Per SAP, multiple imputation was used to impute missing data at Week 24 for reasons other than death or a non-fatal clinical worsening event. Range was based on the minimum and maximum of median scores across the imputed dataset (100 repetitions). The change from baseline to Week 24 in EQ-5D-5L index score is reported.

    Time frame: Baseline and Week 24

07

Results

Posted Aug 22, 2025

Participant flow

Of 255 screened participants, 173 were randomized. One participant was randomized in error and did not receive study treatment. This participant was discontinued from the study and no data was collected. As pre-specified in the statistical analysis plan (SAP), this participant was excluded from all study analyses. Therefore, analyses are presented for 172 participants.

Participant flow — Overall Study
MilestoneSotaterceptPlacebo
Started8686
Completed6960
Not completed1726
Withdrew: Adverse event12
Withdrew: Death711
Withdrew: More than 3 dose delays required per dose adjustment guidelines10
Withdrew: Fridericia's corrected qt interval above 500 ms01
Withdrew: Unwillingness or inability to comply with protocol11
Withdrew: Withdrawal by subject26
Withdrew: Investigator decision20
Withdrew: Started commercial drug35

Outcome measures

PrimaryTime to First Confirmed Morbidity or Mortality Event

Morbidity or mortality events were defined as all-cause death, lung transplantation, or PAH worsening-related hospitalization of ≥24 hours. All events were adjudicated by a blinded, independent committee of clinical experts. Only adjudication-confirmed lung transplantation and PAH worsening-related hospitalization of ≥24 hours were included in the primary analysis. All deaths that are a first event for a participant were included regardless of adjudication. The time from randomization to the first confirmed morbidity or mortality event, calculated using the non-parametric Kaplan-Meier method, is presented.

Time frame:
Up to approximately 31 months
Reported as:
Median · Months
Time to First Confirmed Morbidity or Mortality Event
MonthsSotaterceptPlacebo
Time to First Confirmed Morbidity or Mortality EventNA (25.4 to NA)9.6 (5.9 to 14.8)
SecondaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. As pre-specified in the SAP, all deaths up to data cutoff, including among participants who completed or discontinued the study, were included except for those that occurred after enrollment in the long-term follow-up study (MK-7962-004) or after lung transplantation. The OS for participants, calculated using the non-parametric Kaplan-Meier method, is reported.

Time frame:
Up to approximately 31 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsSotaterceptPlacebo
Overall Survival (OS)NA (25.4 to NA)NA (NA to NA)
SecondaryTransplant-free Survival

Transplant-free survival was defined as the time from randomization to the first lung transplantation or death due to any cause. As pre-specified in the SAP, all deaths up to data cutoff, including among participants who completed or discontinued the study, were included except for those that occurred after enrollment in the long-term follow-up study (MK-7962-004) or after lung transplantation. Transplant-free survival for participants, calculated using the non-parametric Kaplan-Meier method, is reported.

Time frame:
Up to approximately 31 months
Reported as:
Median · Months
Transplant-free Survival
MonthsSotaterceptPlacebo
Transplant-free SurvivalNA (25.4 to NA)NA (NA to NA)
SecondaryPercentage of Participants Who Experienced a Mortality Event

Mortality events were defined as death due to any cause throughout the study. As pre-specified in the SAP, all deaths up to data cutoff, including among participants who completed or discontinued the study, were included except for those that occurred after enrollment in the long-term follow-up study (MK-7962-004) or after lung transplantation. The percent of participants who experienced a mortality event is reported.

Time frame:
Up to approximately 31 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced a Mortality Event
Percentage of ParticipantsSotaterceptPlacebo
Percentage of Participants Who Experienced a Mortality Event12.816.3
SecondaryChange From Baseline in REVEAL Lite 2.0 Risk Score at Week 24

REVEAL Lite 2.0 risk scoring is used to guide PAH treatment decisions. Total score uses 6 variables with each assessed based on contribution to mortality risk. Variables and sub-score ranges: eGFR (0, +1), WHO FC (-1, 0, +1, +2), SBP (0, +1), heart rate (0, +1), 6MWD (-2, -1, 0, +1), and NT-proBNP (-2, 0, +2). Sub-scores are added to a base score of +6 and a total score of 1 to 14 is obtained (≤5=low risk; 6,7=intermediate risk; ≥8=high risk). A higher score = higher risk. Median change and full ranges are reported based on observed data.

Time frame:
Baseline and Week 24
Reported as:
Median · Scores on a scale
Change From Baseline in REVEAL Lite 2.0 Risk Score at Week 24
Scores on a scaleSotaterceptPlacebo
Change From Baseline in REVEAL Lite 2.0 Risk Score at Week 24-3.0 (-9.0 to 2.0)-1.0 (-6.0 to 5.0)
SecondaryPercentage of Participants Achieving a Low or Intermediate (≤7) REVEAL Lite 2 Risk Score at Week 24

REVEAL Lite 2.0 risk scoring is used to guide PAH treatment decisions. Total score uses 6 variables with each assessed based on contribution to mortality risk. Variables and sub-score ranges: eGFR (0, +1), WHO FC (-1, 0, +1, +2), SBP (0, +1), heart rate (0, +1), 6MWD (-2, -1, 0, +1), and NT-proBNP (-2, 0, +2). Sub-scores are added to a base score of +6 and a total score of 1 to 14 is obtained (≤5=low risk; 6,7=intermediate risk; ≥8=high risk). A higher score = higher risk. Per SAP, participants who did not have a REVEAL risk score at Week 24 were considered as non-responders and multiple imputation was not conducted for this endpoint. Comparisons between this analysis reporting non-imputed data should not be made to other REVEAL analyses which included imputation of missing Week 24 data. The percentage of participants who achieved a low or intermediate REVEAL Lite 2.0 score at Week 24 is reported.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving a Low or Intermediate (≤7) REVEAL Lite 2 Risk Score at Week 24
Percentage of ParticipantsSotaterceptPlacebo
Percentage of Participants Achieving a Low or Intermediate (≤7) REVEAL Lite 2 Risk Score at Week 2448.714.3
SecondaryChange From Baseline in NT-proBNP Levels at Week 24

NT-proBNP is secreted by cardiomyocytes in response to ventricular stretch and is an established noninvasive marker of ventricular dysfunction in patients with PAH. Blood samples were collected at baseline and at Week 24 to measure NT-proBNP levels. Median change and full ranges are reported based on observed data.

Time frame:
Baseline and Week 24
Reported as:
Median · pg/mL
Change From Baseline in NT-proBNP Levels at Week 24
pg/mLSotaterceptPlacebo
Change From Baseline in NT-proBNP Levels at Week 24-1336.0 (-21790 to 961)26.0 (-9782 to 16706)
SecondaryChange From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 24

mPAP is a hemodynamic variable associated with PAH severity and was measured measured at baseline and at Week 24 by right heart catheterization (RHC). Median change and full ranges are reported based on observed data.

Time frame:
Baseline and Week 24
Reported as:
Median · mmHg
Change From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 24
mmHgSotaterceptPlacebo
Change From Baseline in Mean Pulmonary Artery Pressure (mPAP) at Week 24-15.0 (-50 to 7)-1.0 (-56 to 25)
SecondaryChange From Baseline in Pulmonary Vascular Resistance (PVR)

PVR is a hemodynamic variable associated with PAH severity and was measured at baseline and at Week 24 by right heart catheterization (RHC). Median change and full ranges are reported based on observed data.

Time frame:
Baseline and Week 24
Reported as:
Median · Dynes*sec/cm^5
Change From Baseline in Pulmonary Vascular Resistance (PVR)
Dynes*sec/cm^5SotaterceptPlacebo
Change From Baseline in Pulmonary Vascular Resistance (PVR)-180.0 (-1504 to 720)-40.0 (-872 to 920)
SecondaryPercentage of Participants Who Improve in WHO FC

The severity of a participant's PAH symptoms was graded using the WHO FC system. WHO functional classification for PAH ranges from Class I (no limitation in physical activity, no dyspnea with normal activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (cannot perform a physical activity without any symptoms, dyspnea at rest). Participants who improve in WHO FC were classified into "Improved", "No change", or "Worsened" (Improved = reduction in FC; Worsened = increase in FC; No change = no change in FC). The percentage of participants who had improvement from baseline in WHO FC at the end of the treatment period is reported.

Time frame:
Baseline and up to approximately 31 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Improve in WHO FC
Percentage of ParticipantsSotaterceptPlacebo
Percentage of Participants Who Improve in WHO FC54.730.2
SecondaryChange From Baseline in 6MWD at Week 24

6MWD was measured using the 6-Minute Walk Test (6MWT). The 6MWT measures the distance covered in 6 minutes and is intended to measure changes in functional exercise capacity. Each participant's 6MWD was measured at baseline and at 24 weeks. An increase in the distance walked during the 6MWT indicated improvement in functional exercise capacity. Median change and full ranges are reported based on observed data.

Time frame:
Baseline and Week 24
Reported as:
Median · Meters
Change From Baseline in 6MWD at Week 24
MetersSotaterceptPlacebo
Change From Baseline in 6MWD at Week 2446.00 (-144.9 to 297.0)22.00 (-150.0 to 387.0)
SecondaryChange From Baseline in Cardiac Output (CO) at Week 24

CO is a prognostic hemodynamic parameter measured at baseline and at Week 24 by RHC. Median change and full ranges are reported based on observed data.

Time frame:
Baseline and Week 24
Reported as:
Median · Liters/minute
Change From Baseline in Cardiac Output (CO) at Week 24
Liters/minuteSotaterceptPlacebo
Change From Baseline in Cardiac Output (CO) at Week 240.02 (-3.1 to 2.2)0.20 (-2.2 to 2.4)
SecondaryChange From Baseline in European Quality of Life (EuroQoL)-5 Dimensions-5 Levels (EQ-5D-5L) Index Score at Week 24

EQ-5D-5L is a standardized measure of health status, consisting of 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each assessed on a 5-point scale (1=no problem, 2=slight problems, 3=moderate problems, 4=severe problems, 5=extreme problems). Participants score each dimension based on their health that day and their responses are used to generate a health index score. Index scores could range from \<0 (a health state equivalent to dead with negative values representing a state worse than dead) to 1 (full health). Higher scores indicated better health and a positive change in score indicated improved overall health. Per SAP, multiple imputation was used to impute missing data at Week 24 for reasons other than death or a non-fatal clinical worsening event. Range was based on the minimum and maximum of median scores across the imputed dataset (100 repetitions). The change from baseline to Week 24 in EQ-5D-5L index score is reported.

Time frame:
Baseline and Week 24
Reported as:
Median · Scores on a Scale
Change From Baseline in European Quality of Life (EuroQoL)-5 Dimensions-5 Levels (EQ-5D-5L) Index Score at Week 24
Scores on a ScaleSotaterceptPlacebo
Change From Baseline in European Quality of Life (EuroQoL)-5 Dimensions-5 Levels (EQ-5D-5L) Index Score at Week 240.060 (-1.020 to 0.637)0.017 (-0.358 to 0.740)

Adverse events

Collected over Up to approximately 31 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sotatercept13/86 (15.1%)52/86 (60.5%)82/86 (95.3%)
Placebo20/86 (23.3%)64/86 (74.4%)77/86 (89.5%)
Most frequent serious events
Showing 10 of 140
Most frequent serious events
EventSotaterceptPlacebo
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders4/8624/86
Right ventricular failureCardiac disorders2/8617/86
Cardiac failureCardiac disorders4/868/86
PneumoniaInfections and infestations8/864/86
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders0/866/86
Atrial fibrillationCardiac disorders5/860/86
DyspnoeaRespiratory, thoracic and mediastinal disorders0/864/86
Supraventricular tachycardiaCardiac disorders3/861/86
COVID-19Infections and infestations3/861/86
SepsisInfections and infestations3/861/86
Most frequent other events
Showing 10 of 46
Most frequent other events
EventSotaterceptPlacebo
EpistaxisRespiratory, thoracic and mediastinal disorders39/866/86
HeadacheNervous system disorders23/8622/86
DiarrhoeaGastrointestinal disorders22/8615/86
TelangiectasiaSkin and subcutaneous tissue disorders22/863/86
Oedema peripheralGeneral disorders12/8620/86
DyspnoeaRespiratory, thoracic and mediastinal disorders13/8617/86
NauseaGastrointestinal disorders16/8615/86
HypokalaemiaMetabolism and nutrition disorders16/8614/86
FatigueGeneral disorders13/8614/86
COVID-19Infections and infestations14/8614/86

Baseline characteristics

Of the 173 participants randomized in the study, one participant was randomized in error to the placebo arm and then immediately discontinued. This participant did not receive study treatment, and no data was collected. As pre-specified in the SAP, this participant was excluded from all study analyses. 4 participants were randomized in violation of the protocol with a REVEAL score of \<9.

Age, Continuous
Age, Continuous(Years)SotaterceptPlaceboTotal
Mean55.3 ± 14.353.5 ± 14.354.4 ± 14.3
Sex: Female, Male
Sex: Female, Male(Participants)SotaterceptPlaceboTotal
Female6171132
Male251540
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SotaterceptPlaceboTotal
Hispanic or Latino61218
Not Hispanic or Latino7873151
Unknown or Not Reported213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SotaterceptPlaceboTotal
American Indian or Alaska Native011
Asian437
Native Hawaiian or Other Pacific Islander000
Black or African American549
White7376149
West Indian101
More than one race112
Unknown or Not Reported213
Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Score
Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) Lite 2.0 Score(Participants)SotaterceptPlaceboTotal
<9134
9 to 105957116
≥11262652
PAH Subtype
PAH Subtype(Participants)SotaterceptPlaceboTotal
Idiopathic PAH424486
Heritable PAH11718
Drug or toxin-induced PAH6511
PAH associated with connective tissue disease222648
PAH associated with simple, congenital systemic-to-pulmonary shunts >1 year following shunt repair549
08

Study locations

57 sites
  • Arizona Pulmonary Specialists ( Site 1010)
    Phoenix, Arizona 85013, United States
  • David Geffen School of Medicine at UCLA ( Site 1068)
    Los Angeles, California 90095, United States
  • University of California Irvine ( Site 1086)
    Orange, California 92868-2994, United States
  • University of California San Diego Medical Center ( Site 1002)
    San Diego, California 92037, United States
  • University of California San Francisco ( Site 1019)
    San Francisco, California 94118, United States
  • University of Colorado Hospital ( Site 1013)
    Aurora, Colorado 80045, United States
  • The George Washington University Medical Faculty Associates ( Site 1025)
    Washington D.C., District of Columbia 20037, United States
  • Mayo Clinic Jacksonville - PPDS ( Site 1045)
    Jacksonville, Florida 32224, United States
  • AdventHealth Medical Group Advanced Lung Disease ( Site 1058)
    Orlando, Florida 32804, United States
  • Northside Hospital ( Site 1073)
    Atlanta, Georgia 30342, United States
  • University Of Iowa Hospitals and Clinics ( Site 1050)
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center ( Site 1020)
    Kansas City, Kansas 66160, United States
  • Tufts Medical Center - PPDS ( Site 1012)
    Boston, Massachusetts 02111, United States
  • Brigham and Women's Hospital ( Site 1014)
    Boston, Massachusetts 02115, United States
  • University of Michigan ( Site 1011)
    Ann Arbor, Michigan 48109, United States
  • Washington University School of Medicine ( Site 1022)
    St Louis, Missouri 63110, United States
  • University of Nebraska Medical Center ( Site 1053)
    Omaha, Nebraska 68105, United States
  • University of New Mexico Health Sciences Center ( Site 1048)
    Albuquerque, New Mexico 87131, United States
  • University of Rochester Medical Center - PPDS ( Site 1039)
    Rochester, New York 14642-0001, United States
  • Duke University Medical Center ( Site 1026)
    Durham, North Carolina 27713, United States
  • University of Cincinnati Medical Center ( Site 1035)
    Cincinnati, Ohio 45267-0558, United States
  • The Cleveland Clinic Foundation. ( Site 1065)
    Cleveland, Ohio 44103-3736, United States
  • Medical University of South Carolina - PPDS ( Site 1003)
    Charleston, South Carolina 29425, United States
  • Statcare Pulmonary Consultants - Knoxville ( Site 1031)
    Knoxville, Tennessee 37909, United States
  • University Of Texas Southwestern Medical Center ( Site 1038)
    Dallas, Texas 75390, United States
  • Medical College of Wisconsin - Froedtert Hospital ( Site 1051)
    Milwaukee, Wisconsin 53226, United States
  • St Vincent's Hospital Sydney ( Site 1102)
    Darlinghurst, New South Wales 2010, Australia
  • John Hunter Hospital ( Site 1101)
    New Lambton Heights, New South Wales 2305, Australia
  • Hôpital Erasme ( Site 1402)
    Anderlecht, Bruxelles-Capitale, Region de 1070, Belgium
  • UZ Leuven Campus Gasthuisberg ( Site 1401)
    Leuven, Vlaams-Brabant 3000, Belgium
  • Peter Lougheed Centre ( Site 2102)
    Calgary, Alberta T1Y 6J4, Canada
  • Jewish General Hospital ( Site 2103)
    Montreal, Quebec H3T 1E2, Canada
  • Hôpitaux Universitaires de Strasbourg ( Site 1307)
    Strasbourg, Bas-Rhin 67000, France
  • Centre Hospitalier Universitaire de Toulouse. ( Site 1315)
    Toulouse, Haute-Garonne 31059, France
  • CHU de Nancy - Hôpital de Brabois Adultes ( Site 1308)
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54511, France
  • CHRU Lille ( Site 1306)
    Lille, Nord 59037, France
  • Hôpital Louis Pradel ( Site 1317)
    Bron, Rhone 69500, France
  • CHU Bicêtre ( Site 1304)
    Le Kremlin-Bicêtre, Val-de-Marne 94275, France
  • CHU de Poitiers ( Site 1316)
    Poitiers, Vienne 86021, France
  • Thoraxklinik-Heidelberg gGmbH ( Site 1509)
    Heidelberg, Baden-Wurttemberg 69126, Germany
  • Krankenhaus Neuwittelsbach ( Site 1510)
    München, Bavaria 80639, Germany
  • Universitaetsklinikum Giessen und Marburg GmbH ( Site 1512)
    Giessen, Hesse 35392, Germany
  • Medizinische Hochschule Hannover ( Site 1505)
    Hanover, Lower Saxony 30625, Germany
  • Uniklinik Köln ( Site 1511)
    Cologne, North Rhine-Westphalia 50937, Germany
  • Universitätsklinikum des Saarlandes ( Site 1513)
    Homburg, Saarland 66424, Germany
  • Universitätsklinikum Carl Gustav Carus an der TU Dresden. ( Site 1501)
    Dresden, Saxony 01307, Germany
  • Lady Davis Carmel Medical Center ( Site 1705)
    Haifa, 34362, Israel
  • Ospedale S. Giuseppe Multimedica ( Site 2403)
    Milan, Lombardy 20123, Italy
  • La Sapienza-Università di Roma-Policlinico Umberto I ( Site 2402)
    Roma, 161, Italy
  • Instituto Nacional De Cardiologia Dr. Ignacio Chavez ( Site 2503)
    Mexico City, Mexico City 14080, Mexico
  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez" ( Site 2504)
    Monterrey, Nuevo León 64460, Mexico
  • Unidad de Investigación Clínica en Medicina, S.C ( Site 2505)
    Monterrey, Nuevo León 64718, Mexico
  • VU Medisch Centrum ( Site 2601)
    Amsterdam, North Holland 1081 HV, Netherlands
  • Hospital Universitario 12 de Octubre ( Site 1603)
    Madrid, 28041, Spain
  • Royal Papworth Hospital ( Site 1208)
    Cambridge, Cambridgeshire CB23 3RE, United Kingdom
  • Royal Brompton Hospital ( Site 1206)
    London, London, City of SW3 6JY, United Kingdom
  • Imperial College Healthcare NHS Trust ( Site 1203)
    London, London, City of W2 1NY, United Kingdom
09

References and documents

Publications

  • Humbert M, McLaughlin VV, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, Preston IR, Souza R, Waxman AB, Moles VM, Savale L, Vizza CD, Rosenkranz S, Shi Y, Miller B, Mackenzie HS, Kim SS, Loureiro MJ, Patel MJ, Koglin J, Cornell AG, Hoeper MM; ZENITH Trial Investigators. Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med. 2025 May 29;392(20):1987-2000. doi: 10.1056/NEJMoa2415160. Epub 2025 Mar 31. PubMed 40167274 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jul 2024, 31 months.

Results were first posted in Aug 2025, 1 year after primary completion.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 31 months is below that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2021
First posted
May 21, 2021
StartActual
Dec 1, 2021
Primary completionActual
Jul 26, 2024
CompletionActual
Feb 18, 2025
Results first posted
Aug 22, 2025
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04896008
Responsible party
Sponsor
First posted
May 21, 2021
Start date
Dec 1, 2021
Primary completion
Jul 26, 2024
Completion
Feb 18, 2025
Results posted
Aug 22, 2025
Last update
May 29, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion